Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
11.430
Open
11.215
VWAP
11.03
Vol
977.57K
Mkt Cap
495.98M
Low
10.705
Amount
10.79M
EV/EBITDA(TTM)
--
Total Shares
41.13M
EV
406.41M
EV/OCF(TTM)
--
P/S(TTM)
5.34
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q2
FY2025Q1
32.10M
+27.36%
-0.692
+25.76%
24.80M
+13.5%
-0.790
-13.19%
22.69M
+20.82%
-0.795
-18.04%
Estimates Revision
The market is revising Downward the revenue expectations for UroGen Pharma Ltd. (URGN) for FY2025, with the revenue forecasts being adjusted by -7.24% over the past three months. During the same period, the stock price has changed by -5.20%.
Revenue Estimates for FY2025
Revise Downward
-7.24%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+2.5%
In Past 3 Month
Stock Price
Go Down
-5.20%
In Past 3 Month
7 Analyst Rating
213.29% Upside
Wall Street analysts forecast URGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for URGN is 33.71 USD with a low forecast of 16.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
213.29% Upside
Current: 10.760
Low
16.00
Averages
33.71
High
55.00
213.29% Upside
Current: 10.760
Low
16.00
Averages
33.71
High
55.00
Guggenheim
Kelsey Goodwin
Strong Buy
Reiterates
n/a
2025-04-29
New
Reason
Guggenheim
Kelsey Goodwin
Price Target
n/a
2025-04-29
New
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$25
2025-04-28
New
Reason
D. Boral Capital
Jason Kolbert
Price Target
$25
2025-04-28
New
Maintains
Strong Buy
Reason
UroGen Pharma announced an updated 18-month Duration of Response, DOR, of 80.6%, by Kaplan-Meier estimate, from the Phase 3 ENVISION trial of UGN-102 for intravesical solution, an investigational treatment for recurrent LG-IR-NMIBC. These data were featured in an Oral Presentation Session at the AUA 2025 Annual Meeting in Las Vegas, Nevada. "This new update from the pivotal ENVISION trial of UGN-102 demonstrated a compelling probability of remaining in complete response of 80.6% at 18 months in patients who achieved a complete response at three months," said Sandip Prasad M.D., M.Phil., Director of Genitourinary Surgical Oncology, Vice Chair of Urology at Morristown Medical Center/Atlantic Health System, NJ, and Principal Investigator of the ENVISION trial. "Low-grade bladder cancer is a persistent cancer that frequently recurs and comes with its own risks. There is a significant unmet need in finding treatment options for patients with recurrent low-grade bladder cancer."
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$55
2025-04-28
New
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$55
2025-04-28
New
Reiterates
Strong Buy
Reason
Goldman Sachs
Paul Choi
Hold
Maintains
$22 → $16
2025-04-17
Reason
Goldman Sachs
Paul Choi
Price Target
$22 → $16
2025-04-17
Maintains
Hold
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$25
2025-03-13
Reason
D. Boral Capital
Jason Kolbert
Price Target
$25
2025-03-13
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$64 → $55
2025-03-11
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$64 → $55
2025-03-11
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Urogen Pharma Ltd (URGN.O) is -3.92, compared to its 5-year average forward P/E of -3.58. For a more detailed relative valuation and DCF analysis to assess Urogen Pharma Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.58
Current PE
-3.92
Overvalued PE
-2.38
Undervalued PE
-4.79
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.65
Current EV/EBITDA
-3.49
Overvalued EV/EBITDA
-1.60
Undervalued EV/EBITDA
-5.70
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
5.70
Current PS
4.27
Overvalued PS
10.17
Undervalued PS
1.24
Financials
Annual
Quarterly
FY2024Q4
YoY :
+4.40%
24.57M
Total Revenue
FY2024Q4
YoY :
+89.32%
-27.66M
Operating Profit
FY2024Q4
YoY :
+44.19%
-37.51M
Net Income after Tax
FY2024Q4
YoY :
-9.72%
-0.65
EPS - Diluted
FY2024Q4
YoY :
+5.23%
-13.73M
Free Cash Flow
FY2024Q4
YoY :
-0.38%
89.94
Gross Profit Margin - %
FY2024Q4
YoY :
+15.99%
-107.37
FCF Margin - %
FY2024Q4
YoY :
+38.11%
-152.71
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 326.91% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
132.9K
USD
2
6-9
Months
31.1K
USD
2
0-12
Months
67.4K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.3M
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
1.3M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
4
3.9M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 326.91% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
132.9K
USD
2
6-9
Months
31.1K
USD
2
0-12
Months
67.4K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
URGN News & Events
Events Timeline
2025-04-27 (ET)
2025-04-27
17:56:01
UroGen Pharma announces long-term follow up data from OPTIMA II Phase 2b study
2025-04-27
17:55:13
UroGen Pharma announces patient-reported outcomes on UGN-102
2025-04-27
17:54:15
UroGen Pharma announces updated 18-month DOR data from Phase 3 ENVISION trial
Sign Up For More Events
Sign Up For More Events
News
9.0
04-28BenzingaPinnedUroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates
9.0
04-27NewsfilterPinnedNew Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
9.0
04-27NewsfilterPinnedNew Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
Sign Up For More News
People Also Watch
LAAC
Lithium Americas (Argentina) Corp
2.740
USD
0.00%
LINC
Lincoln Educational Services Corp
17.130
USD
-0.06%
NNOX
Nano-X Imaging Ltd
4.990
USD
-3.11%
FFIC
Flushing Financial Corp
12.450
USD
+0.81%
NFBK
Northfield Bancorp Inc
10.550
USD
+3.94%
GLRE
Greenlight Capital Re Ltd
13.230
USD
+0.68%
BCAL
Southern California Bancorp
14.070
USD
+1.88%
FMNB
Farmers National Banc Corp
13.220
USD
+1.07%
GHM
Graham Corp
30.480
USD
-1.30%
RNAC
Cartesian Therapeutics Inc
11.900
USD
-2.54%
FAQ
What is Urogen Pharma Ltd (URGN) stock price today?
The current price of URGN is 10.76 USD — it has decreased -4.44 % in the last trading day.
What is Urogen Pharma Ltd (URGN)'s business?
What is the price predicton of URGN Stock?
What is Urogen Pharma Ltd (URGN)'s revenue for the last quarter?
What is Urogen Pharma Ltd (URGN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Urogen Pharma Ltd (URGN)'s fundamentals?
How many employees does Urogen Pharma Ltd (URGN). have?